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Abstract: The oncogenic BRAF(V600E) mutation is common in melanomas as well as
moles. The roles that this mutation plays in the early events in the development of melanoma
are poorly understood. This study demonstrates that expression of BRAF(V600E) is not only
clastogenic, but synergizes for clastogenesis caused by exposure to ultraviolet radiation in the
300 to 320 nM (UVB) range. Expression of BRAF(V600E) was associated with induction
of Chk1 pS280 and a reduction in chromatin remodeling factors BRG1 and BAF180. These
alterations in the Chk1 signaling pathway and SWI/SNF chromatin remodeling pathway may
contribute to the clastogenesis and UVB sensitivity. These results emphasize the importance
of preventing sunburns in children with developing moles.
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1. Introduction
The oncogenic BRAF(V600E) mutation is a common mutation in many cancers and precancerous
lesions making it an important diagnostic marker and treatment target [1–3]. Of all cancers, the
BRAF(V600E) mutation is most prevalent in melanoma, being observed in about 50% of melanomas and
a similarly large fraction of melanocytic nevi [4,5]. Because the oncogenic BRAF(V600E) mutation is
observed in precancerous nevi it is thought to be a very early mutation in the development of melanoma.
With the epidemiological link between oncogenic BRAF(V600E) and melanoma being well established,
the contribution of BRAF(V600E) to melanoma development is under intense investigation. In vitro
expression of BRAF(V600E) in normal human cells, including melanocytes, results in a very rapid
oncogene-induced growth arrest phenotype that is independent of p53 [6]. The effect of oncogenic
BRAF(V600E) expression in nevi appears to be more complex, with a recent report suggesting that nevi
may in fact not be as senescent as previously believed [7]. Slow replication of melanocytes in nevi may
be necessary to fix into the genome mutations that are needed for the development of melanoma.
The Loeb mutator theory of human carcinogenesis holds that the background rate of mutation in
human cells is too low to generate the 6–8 independent mutations that are needed to produce a cancer, so
an early event in malignant transformation is a mutation (or epigenetic alteration) that increases the rate
of mutation [8,9]. Previous reports have suggested that expression of BRAF(V600E) in cells may result
in DNA damage as measured by micronuclei formation or by comet assay [10,11]. These studies both
used proxies as a measure of the DNA damage present in the cell and neither suggested a mechanism
for induction of the damage. A possible mechanism has been put forward that links BRAF(V600E),
an oncogene, to BRCA1, a tumor suppressor [12]. In this model expression of BRAF(V600E) drives
BRCA1 off the chromatin by down-regulation of BRIP1. This would make the cells phenotypically
BRCA1 null as seen in reports where BRCA1 was excluded from the nucleus through expression
of a dominant-negative BARD1 that blocks DNA damage-induced foci formation [13]. However
expression of BRCA1 is growth-dependent and it is not clear if the observed reduction in BRCA1 was
completely separate from the induction of oncogene-induced growth arrest. We report here the finding
that expression of oncogenic BRAF(V600E) is directly clastogenic, potentially fulfilling the role of a
Loeb mutator and that its expression sensitized cells to UVB-induced clastogenesis. We also present
evidence for a model that expression of oncogenic BRAF(V600E) results in altered regulation of Chk1
and a reduction in the amount of BAF180, potentially explaining the clastogenesis and UVB sensitivity
that is independent of oncogene-induced growth arrest.
2. Results and Discussion
2.1. Engineering and Validation of Cell Lines
A melanoma cell line that is wild-type for BRAF and NRAS, and engineered to express oncogenic
BRAF(V600E) has been described previously [14]. Using the same technique we engineered a second
melanoma line that is wild-type for BRAF and NRAS. The DNA damage checkpoint responses have been
described previously for both of these melanoma lines [15–17]. Neither has a functional G1 checkpoint
response due to alterations in p53 signaling. Both have an intact G2 checkpoint response. Figure 1
shows that the expression of the V5-BRAF(V600E) can be regulated by the amount of doxycycline
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added to the medium in the two melanoma cell lines with the RPMI8322 + TetON + V5-BRAF(V600E)
line exhibiting induction at a lower doxycycline concentration (0.01 µg/mL) than the PMWK + TetON +
V5-BRAF(V600E) line (0.1 µg/mL). The western blot shown in Figure 1A demonstrated a clear increase
in the amount of the V5 tag present as the amount of doxycycline was increased. The exogenous
V5-BRAF was active as seen by the induction of phospho-MEK 1/2 and the correlation between
activation of MEK1/2 and the amount of V5-BRAF present in the extract (Figure 1B). The RPMI8322
line not only exhibited a lower threshold for detection of V5-BRAF(V600E) but also exhibited a much
greater fold induction of phospho-MEK1/2 than seen in the PMWK line.
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Figure 1. Induction of V5-tagged oncogenic BRAF(V600E) in RPMI8322 and PMWK cells. 
(A) Western Blot of whole cell lysates showing time and doxycycline concentration 
dependent induction of V5-BRAF(V600E). (B) Quantification of pMEK1/2 signal from 
panel A normalized to 0 µg/mL doxycycline control. 
Since expression of oncogenic BRAF causes oncogene-induced growth arrest we tested whether this 
happened in our cell lines. As shown in Figure 2, expression of V5-BRAF(V600E) blocked clonal 
expansion of the cell lines in a dose-dependent manner. In agreement with the different levels of 
expression of V5-BRAF(V600E) shown in Figure 1A, the RPMI8322 line reduced colony formation to 
a greater extent than the PMWK line at the lower doxycycline concentrations. These results confirm 
both the biochemistry and biology of the system.  
Figure 1. Induction of V5-tagged oncogenic BRAF(V600E) in RPMI8322 and PMWK
cells. (A) Western Blot of whole cell lysates showing time and doxycycline concentration
dependent induction of V5-BRAF(V600E). (B) Quantification of pMEK1/2 signal from
panel A normalized to 0 µg/mL doxycycline control.
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Figure 2. Oncogenic BRAF induced reduction in clonogenic expansion is dose dependent 
in all cell lines. Colony assay set up as described in the Experimental section. Each bar 
represents three to four independent determinations. 
2.2. Oncogenic BRAF Induced Chromosomal Aberrations 
Previous reports have suggested that V5-BRAF(V600E) expression may result in chromosomal 
breaks and a DNA damage signal in cells as measured by comet assay, micronuclei formation, or 
induction of phosphorylated γH2aX [10,11]. We extended these observations by directly scoring 
metaphase preparations for damaged chromosomes. Expression of V5-BRAF(V600E) caused structural 
chromosomal aberrations in the RPMI8322 + TetON + V5-BRAF(V600E) and PMWK + TetON +  
V5-BRAF(V600E) cells after 48 h of induction. There was no detectable clastogenesis in either cell line 
after 24 h of oncogenic BRAF induction (not shown). Figure 3A shows representative examples of the 
types of damage observed. The aberrations observed in both cell lines were primarily chromatid breaks 
with a smaller number of exchange aberrations and a few dicentrics (Figure 3B). Even with this 
chromosomal damage and in contrast to published reports, we were unable to demonstrate induction of 
a DNA damage response as measured by phospho-ATM, phospho-Chk1 S345, or phospho-Chk2 T68 at 
24 or 48 h induction with 1 μg/mL doxycycline (data not shown). This may be a result of the maximum 
aberration frequency being less than one aberration per metaphase which is equivalent to only a few cGy 
of ionizing radiation [18] or a combination of the different cell lines and different techniques employed 
(western blot in our studies, immunofluorescence in published studies). 
Although both cell lines exhibit similar levels of chromosomal aberrations in the absence of  
V5-BRAF(V600E), the PMWK cell line exhibited a much higher break frequency than the RPMI cell 
line after induction. This may represent an underlying difference in chromatin architecture. The PMWK 
cell line was found to be polyploid with most metaphases having about 90 chromosomes while the RPMI 
cell line was near diploid. The total frequency of the aberrations in the RPMI line did not increase 
significantly with increasing expression of the oncogenic BRAF. The aberrations are unlikely to be due 
to an effect of the doxycycline since incubation of RPMI8322 + TetON cells, parents of the RPMI8322 
Figure 2. Oncogenic BRAF induced reduction in clonogenic expansion is dose dependent
in all cell lines. Colony assay set up as described in the Experimental section. Each bar
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+ TetON + V5-BRAF(V600E) cells, with doxycycline did not increase aberrations (Table S1). This is
the first direct evidence that oncogenic BRAF is clastogenic, making BRAF a potential mutator.
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Figure 3. Oncogenic BRAF(V600E) Induced Clastogenesis. (A) Representative metaphase 
images of each cell line after 48 h incubation in doxycycline; (B) Aberrations per 
chromosome for each cell line. Data represents ≥50 metaphases for each treatment. 
2.3. UVB Sensitivity of Cell Lines 
Melanoma progression is linked to DNA damage caused by exposure to ultraviolet radiation [19]. 
Consistent with this is the observation that in a mouse model of melanoma, expression of oncogenic 
BRAF results in increased tumor burden following exposure to UVB [20]. Therefore it was of interest 
to determine if expression of V5-BRAF(V600E) sensitized cells to UV exposure. We wished to use a 
dose of UVB that did not kill all the cells (as dead cells do not play a role in melanomagenesis) but was 
in the realm of what would be expected for a person to receive from being outside during the summer in 
Figure 3. Oncogenic BRAF(V600E) Induced Clastogenesis. (A) Representative metaphase
images of each cell line after 48 h incubation in doxycycline; (B) Aberrations per
chromosome for each cell line. Data represents ≥50 metaphases for each treatment.
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in mid-latitudes. The sensitivity of the two melanoma cell lines to killing by UVB was determined as
described in the Experimental section and is shown in Figure 4. From these data a D0 value, or dose to
reduce the viable cell population to approximately 37%, was then calculated for each cell line according
to published methods [21]. As previously published for UVC, the RPMI8322 line was found to be
very sensitive to exposure to UVB, exhibiting a D0 of 191 J/m2, presumably due to defective nucleotide
excision repair [22]. PMWK was found to have a D0 value of 254 J/m2. For subsequent experiments a
fluence of UVB was chosen for each cell line that resulted in approximately equal killing.
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Overall the PMWK line exhibited a higher aberration frequency than the RPMI8322 line while the 
RPMI8322 line exhibited more exchange aberrations. The observation of the increased aberration 
frequency in the PMWK cell line was somewhat surprising given that this line is more resistant to UVB 
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Figure 5. Chromosomal aberrations found 24 h after exposure to UVB. (*) No aberrations 
found. ≥50 metaphases scored for each condition. (A) Representative metaphase images 
showing aberrations; (B) Chart showing type of damage and frequency in PMWK + TetON 
+ V5-BRAF(V600E) cells; (C) Chart showing type of damage and frequency in RPMI8322 
+ TetON + V5-BRAF(V600E) cells. 
2.5. Oncogenic BRAF Sensitizes Cells to UVB Clastogenesis 
To determine if expression of oncogenic BRAF had an effect on UVB clastogenesis, cells cultured in 
an amount of doxycycline (1 μg/mL PMWK and 0.1 μg/mL RPMI8322; Figure 1) that results in equal 
induction of V5-BRAF(V600E) and exposed to UVB as before were scored for chromosomal aberrations 
24 h after UVB exposure. Representative metaphases are shown in Figure 6A for both cell lines. Like 
UVB alone, the PMWK (Figure 6B) line exhibited a break frequency much higher than the RPMI8322 
line (Figure 6C). PMWK cells expressing oncogenic BRAF and exposed to a D0 of UVB could not be 
accurately scored. This dose of UVB in the presence of oncogenic BRAF resulted in very few scorable 
metaphases with every chromosome in those few metaphases containing multiple aberrations. At ¼D0 
and ½D0 both lines exhibited a similar pattern of damage with the PMWK line now also showing 
exchange aberrations. 
Figure 5. Chromosomal aberrations found 24 h after exposure to UVB. (*) No aberrations
found. ≥50 metaphases scored for each condition. (A) Representative metaphase images
showing aberrations; (B) Chart showing ty f and frequency in PMWK + TetON
+ V5-BRAF(V600E) cells; (C) Chart sho i age and frequency in RPMI8322
+ TetON + V5-BRAF(V60 E) cells.
2.5. Oncogenic BRAF Sensitizes Cells to UVB Clastogenesis
To determine if expression of oncogenic BRAF had an effect on UVB clastogenesis, cells cultured
in an amount of doxycycline (1 µg/mL PMWK and 0.1 µg/mL RPMI8322; Figure 1) that results in
equal induction of V5-BRAF(V600E) and exposed to UVB as before were scored for chromosomal
aberrations 24 h after UVB exposure. Representative metaphases are shown in Figure 6A for both cell
lines. Like UVB alone, the PMWK (Figure 6B) line exhibited a break frequency much higher than
the RPMI8322 line (Figure 6C). PMWK cells expressing oncogenic BRAF and exposed to a D0 of
UVB could not be accurately scored. This dos of UVB in the prese ce of oncogenic BRAF resulted
in very few scorable m taphases with every ch omoso e in those f w metaphas s cont ining multiple
aberrations. At ¼D0 and ½D0 both lines exhibited a similar pattern of damage with the PMWK line now
also showing exchange aberrations.
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Figure 6. Expression of V5-BRAF(V600E) for 24 h followed by exposure to UVB results 
in enhanced clastogenesis. ≥50 metaphases scored for each condition. (A) Representative 
metaphase images showing aberrations. (B) PMWK + TetON + V5-BRAF(V600E) cells. 
(*) Metaphases were too damaged to score. >7 aberrations per chromosome. (C) Chart 
showing type of damage and frequency in RPMI8322 + TetON + V5-BRAF(V600E) cells. 
The fold-induction of chromosomal aberrations for the different treatments is shown in Table 1. The 
first three columns show the effect of UVB exposure at ¼D0 and ½D0 as well as the effect of oncogenic 
BRAF induction (Dox) on the PMWK and RPMI8322 cell lines. At the lowest fluence of UVB both cell 
lines exhibited a similar induction of aberrations. Combining the ¼D0 of UVB with oncogenic BRAF 
Figure 6. Expression of V5-BRAF(V600E) for 24 h followed by exposure to UVB results
in enhanced clastogenesis. ≥50 metaphases scored for each condition. (A) Representative
metaphase images showing aberrations. (B) PMWK + TetON + V5-BRAF(V600E) cells. (*)
Metaphases were too damaged to score. >7 aberrations per chromosome. (C) Chart showing
type of damage and frequency in RPMI8322 + TetON + V5-BRAF(V600E) cells.
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expression, the resulting induction of aberrations appears to be additive for both cell lines. This is seen in
Table 1 where the frequency of aberrations induced by oncogenic BRAF alone was subtracted from the
frequency of aberrations induced when oncogenic BRAF was combined with UVB exposure (columns
4 and 5). However, increasing the UVB dose to ½D0 in cells expressing oncogenic BRAF resulted in a
fold-increase in the aberrations that was 3.6 and 7.6 times greater than that induced by doxycycline alone
for the PMWK and RPMI8322 cells respectively (Table 1 column 5). At this dose of UVB, combining the
two treatments resulted in a synergistic response. This increased sensitivity to ultraviolet light is likely
the underlying reason the number of nevi a person carries coupled with sun exposure is the greatest risk
factor for melanoma. This finding also fulfills the requirements for oncogenic BRAF to impart a mutator
phenotype to cells harboring the mutation, as postulated by Loeb and colleagues [8,9].
Table 1. Effect of Oncogenic BRAF on UVB Induced Aberrations.
Treatment/Sham (Freq-Dox Freq)/Sham
¼D0 ½D0 * Dox ¼D0 + * Dox ½D0 + * Dox
§ PMWK 4.5 16 7.3 10 28
† RPMI8322 5.0 4.4 3.0 4.6 23
The first three columns show the induction of aberrations caused by UVB or oncogenic BRAF alone. The last
two columns show the induction of aberrations attributable to oncogenic BRAF in cells exposed to both UVB
and dox. (§) PMWK + TetON + V5-BRAF(V600E) cells. (†) RPMI8322 + TetON + V5-BRAF(V600E) cells.
(*) Doxycycline. 1 µg/mL for PMWK cells; 0.1 µg/mL for RPMI8322 cells.
2.6. Mechanisms of BRAF(V600E) Induced Sensitivity
The mechanism responsible for the oncogenic BRAF-induced aberrations and the synergy with UVB
is not obvious. To determine if the sensitivity to UV observed in the oncogenic BRAF-expressing cells
was due to alterations in the repair capacity of the cells we measured nucleotide excision repair (NER)
in the V5-BRAF(V600E) expressing RPMI and PMWK cells exposed to a D0 dose of UVB. Cells were
assayed for repair of CPD’s and 6-4PP as previously described [22]. Induction of oncogenic BRAF did
not alter repair of UVB-induced DNA damage in these cells (data not shown).
2.6.1. Alteration of BRCA1 Function
The exchange aberrations and breaks observed after induction of V5-BRAF(V600E) and the increased
sensitivity to UVB suggested that misregulation of BRCA1 might be a possible cause. BRCA1 is
required for efficient repair of UV damage [23] as well as regulation of homologous recombination [24].
Indeed a publication suggested that oncogenic BRAF could reduce the amount of BRCA1 associated
with chromatin by down-regulation of BRIP1 [12]. We measured the amount of cytoplasmic and
chromatin associated BRCA1 and BRIP1 in cells 24 and 48 h after induction of the V5-BRAF(V600E).
In three independent experiments using RPMI8322 + TetON + V5-BRAF(V600E) and PMWK +
TetON + V5-BRAF(V600E) cell lines, we found that that amount of BRCA1 in the cells after
V5-BRAF(V600E) induction was variable and did decrease with time in doxycycline. Figure 7 shows a
representative western Blot from these experiments. To explore the possibility that this variability was
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due to the cell type, we constructed a normal human fibroblast line to express V5-BRAF(V600E) as
described in the Experimental section. This line induces V5-BRAF(V600E) similar to that of PMWK
+ TetON + V5-BRAF(V600E) and this induction causes oncogene-induced growth arrest as seen by
an inhibition in colony formation (Figure S1). The location and amount of BRCA1 and BRIP1 in the
fibroblast line was consistent with that observed in Figure 7 (Figure S2). These results suggested the
possibility that the amount of BRCA1 might be varying as a result of how well the cells were growing.
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Figure 7. Western blot cells grown for (A) 24 h in doxycycline or (B) 48 h in doxycycline. 
Loading normalized to cell number. Cyto cytoplasm; Chrm chromatin fraction. Fractionation 
described in the Experimental section. 
BRCA1 is known to exhibit cell cycle dependent expression [25,26]. To test whether proliferation 
affected expression of BRCA1 RPMI8322 + TetON + V5-BRAF(V600E) cells were grown with 
increasing amounts of doxycycline and labeled with BrdU to determine the S-phase content prior to 
harvest. Figure 8 shows the total amount of BRCA1 in RPMI8322 + TetON + V5-BRAF(V600E) cells, 
normalized to topoisomerase IIβ, a chromatin marker, went down as the amount of V5-BRAF(V600E) 
went up. However, the highest induction of V5-BRAF(V600E) resulted in an 84% reduction in S-phase 
and a 73% reduction in the amount of BRCA1 in the cells. Based on these results we could not rule out 
oncogene-induced growth arrest as the cause of the reduction in BRCA1 expression. 
Figure 7. Western blot cells grown for (A) 24 h in doxycycline or (B) 48 h in
doxycycline. Loading normalized to cell number. Cyto cytoplas ; Chrm chromatin fraction.
Fractionation described in the Experimental section.
BRC 1 is kno n to exhibit cell cycle dependent expression [25,26]. To test hether proliferation
affected expression of BRCA1 RP I8322 + TetON + V5-BRAF(V600E) cells were grown with
increasing amounts of doxycycline and labeled with BrdU to determine the S-phase content prior to
harvest. Figure 8 shows the total amount of BRCA1 in RP I8322 + TetON + V5-BRAF(V600E) cells,
normalized to topoisomerase IIβ, a chromatin marker, went down as the amount of V5-BRAF(V600E)
went up. However, the highest induction of V5-BRAF(V600E) resulted in an 84% reduction in S-phase
and a 73% reduction in the amount of BRCA1 in the cells. Based on these results we could not rule out
oncogene-induced growth arrest as the cause of the reduction in BRCA1 expression.
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Figure 8. Correlation of the amount of BRCA1 present in RPMI8322 + TetON +  
V5-BRAF(V600E) cells with S-phase fraction of the cell population. (A) FLOW cytometry 
profiles of cells incubated with increasing amounts of doxycycline. (B) Amount of BRCA1 
present as a percentage of the no doxycycline control. (C) Western Blot used to generate 
chart in panel B.  
2.6.2. Alteration of Chk1 Signaling 
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resulted in a substantial increase in the amount of pChk1 (S280). Figure 9 is a composite western blot of 
all three cell lines grown with or without doxycycline for 24 or 48 h. As shown in Figure 9C, all three 
cell lines showed an increase in the amount of pChk1 (S280) at both 24 and 48 h. The fold increase in 
the F1-hTERT + TetON + V5-BRAF(V600E) cells was always slightly less than that seen in the two 
melanoma lines. The apparent cause of this is the fibroblasts have a slightly higher amount of pChk1 
(S280) in the uninduced cells. 
Figure 8. Correlation of the amount of BRCA1 present in RPMI8322 + TetON +
V5-BRAF(V600E) cells with S-phase fraction of the cell population. (A) FLOW cytometry
profiles of cells incubated with increasing amounts of doxycycline. (B) Amount of BRCA1
present as a percentage of the no doxycycline control. (C) Western Blot used to generate
chart in panel B.
. . . lt r ti f i li
il it i t r li l t t t t r l ti f , r lt r ti s i , r
res si le for the oncogenic BRAF-induced clastogenesis or UVB sensitivity, an ther possibility
was our previously published observation that expression of oncogenic BRAF attenuates the DNA
damage-induced G2 checkpoint response [14]. Chk1 is a central protein in the G2 checkpoint response.
Any alterations in the regulation of Chk1 could impact this checkpoint. Consistent with the possibility
of Chk1 misregulation was the observation with all three cell lines that induction of V5-BRAF(V600E)
always resulted in a substantial increase in the amount of pChk1 (S280). Figure 9 is a composite western
blot of all three cell lines grown with or without doxycycline for 24 or 48 h. As shown in Figure 9C, all
three cell lines showed an increase in the amount of pChk1 (S280) at both 24 and 48 h. The fold increase
in the F1-hTERT + TetON + V5-BRAF(V600E) cells was always slightly less than that seen in the two
melanoma lines. The apparent cause of this is the fibroblasts have a slightly higher amount of pChk1
(S280) in the uninduced cells.
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oncogenic BRAF activates p90RSK1 through the phosphorylation of p90RSK1 by ERK [32] which 
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inhibition of RSK1 or MEK results in a reduction in the amount of Chk1 pS280 and an increase in the
amount of Chk1 kinase activity [33].
2.6.3. Alteration of SWI/SNF Chromatin Remodeling Complex
A final possibility for explaining the clastogenesis induced by the oncogenic BRAF and the synergy
with UVB exposure is alteration of the SWI/SNF chromatin remodeling complex. As shown in Figures 3,
5 and 6 the PMWK cell line exhibited higher frequencies of chromosomal aberrations from oncogenic
BRAF or UVB alone and when combined. A possible explanation for this observation is that the PMWK
cells do not express BRG1 (Figure S3). Loss of BRG1 has been shown to increase the frequency of
DNA damage after exposure to UVC [34]. When all the cells used in this study were examined for
BRG1 and BAF180 expression it was found that expression of oncogenic BRAF reduced the expression
of BRG1 in the two cell lines that expressed it and reduced the expression of BAF180 in all three cell
lines (Figure 10).
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This study also suggests possible implications in other cancers such as colon cancer where the oncogenic
BRAF mutation has been reported in 70% of the tumors exhibiting the highest level of microsatellite
instability [35]. This may imply that the oncogenic BRAF may act synergistically in other cancers to
ultimately increase the mutation frequency in these tumors.
3. Experimental Section
3.1. Molecular Biology
A V5-BRAF(V600E) expression vector was constructed by cloning a synthetic V5-BRAF(V600E)
DNA cassette into the pRetro-X-Advanced (Clonetech, Mountain View, CA, USA) vector. Vector
construction and sequence verification of the vector was done by Blue Heron Bio (Bothell, WA, USA).
3.2. Cell Culture and Viral Transduction
Melanoma cell lines RPMI8322 and PMWK were grown in DMEM high glucose (Life Technologies,
Carlsbad, CA, USA or Cellgro, Manassas, VA, USA) supplemented with 10% Benchmark fetal calf
serum (Gemini, West Sacramento, CA, USA), and 200 mM L-glutamine (Life Technologies) at 37 ◦C in
a 5% CO2 atmosphere. Packaging of retroviral vectors and transduction of cells was done as previously
described [36]. The cell lines were first transduced with the Retro-X-TetON vector (Clonetech).
Following selection in 500 µg/mL G418 for two weeks the cells were then transduced with the
V5-BRAF(V600E) expression vector. The V5-BRAF(V600E) vector was selected for two weeks in
150 µg/mL hygromycin B.
3.3. Cytotoxicity Assays
The ability of the oncogenic V5-BRAF(V600E) to reduce clonogenic survival was assessed as
follows. Cells were trypsonized to achieve a single cell suspension. The viable cell count was determined
by trypan blue exclusion and counting cells in a heamocytometer. Three hundred viable cells were seeded
per 10 cm diameter dish in triplicate in 10 mL of media containing various amounts of doxycycline. The
media was changed on day seven, maintaining the doxycycline. On day 14 the colonies were fixed and
stained with a solution of 40% methanol and 0.05% crystal violet.
UVB cytotoxicity was determined by seeding 300 viable cells per dish as above. Twenty-four
hours after seeding the media was removed and the cells exposed to various fluences of UVB with the
lids on the dishes in an open cabinet to the output from two high intensity broad range UVB lamps
(FS20T12/UVB, National Biological Corp., Cleveland, OH, USA) at a fluence of 3.13 J/s/m2. By
keeping the lids on the dishes all wavelengths less than about 300 nM were filtered out resulting in a
UVB profile more similar to that found in sunlight [37]. The UVB source was calibrated with a UVX
Radiometer (Ultra-Violet Products, Inc., Upland, CA, USA) using an UVX-31 sensor. The cells were
grown for 14 days after exposure and then stained as described above. Calculations to determine the D0
value were done as previously published [21].
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3.4. Western Blotting
Whole cell extracts were prepared by solubilizing cell pellets in urea buffer (8 M urea, 100 mM
monobasic sodium phosphate, 10 mM tris pH 7.0) for 30 min on ice prior to protein quantification.
Proteins were quantified using a Qubitr (Life Technologies) according to manufactures protocol. Cells
were fractionated into cytoplasmic and chromatin fractions by previously published methods [38].
Primary antibodies for western blots used in this study are listed in Table 2.
Table 2. Primary antibodies used in the study.
Antibody Dilution Source Catalogue Number
BRCA1 1:1000 Milli-Pore 07-434
Top2β 1:1000 BD Transduction Labs 611493
BRIP1/BACH1 1:1000 Cell Signaling 4578
BRG1 1:1000 Bethyl A300-813A
BRAF 1:1000 Cell Signaling 9434
V5 1:1000 Sigma-Aldrich 012M4796
Chk1 1:1000 Santa Cruz SC-8408
pChk1 (S345) 1:1000 Cell Signaling 2348
pChk1 (S280) 1:1000 Epitomics 2643-1
Mek1/2 1:1000 Cell Signaling 4694
pMek1/2 (S217/S221) 1:1000 Cell Signaling 9154
Pan-Actin 1:5000 Novus Biologics NB600-535
The primary antibodies were detected using fluorescently labeled anti-mouse and anti-rabbit
secondary antibodies at a dilution of 1:10,000 and obtained from Li-Cor (Goat Anti-Mouse IRDye
680RD; Cat.#926-68070 and Goat Anti-Rabbit IRDye 800CW; Cat.#926-32211). The proteins were
visualized by scanning the blots on a Li-Cor Odysseyr (Lincoln, NE, USA scanner. Images were
quantified using the Visual Studio 4.0 software package (Li-Cor) unless noted otherwise.
4. Conclusions
Expression of oncogenic BRAF(V600E) was clastogenic in two human melanoma cell lines. The
melanoma cell lines provided an opportunity to study mitotic chromosome structure after induction of the
oncogene but prior to cessation of cell division. Equivalent studies were done with a TERT-expressing,
immortal human melanocyte line but no mitotic cells could be recovered two days after induction of
BRAF(V600E) (results not shown). As BRAF(V600E) attenuated the DNA damage G2 checkpoint [14]
it may be that the relaxation of this checkpoint permitted the analysis of mitotic chromosomes in addition
to sensitizing cells to UVB-induced clastogenesis. Oncogenic BRAF(V600E) sensitized the melanoma
cells to exposure to doses of UVB that would be expected to result in only mild erythema in most
Caucasians [39]. The type of DNA damage observed in the BRAF(V600E) expressing cells exposed
to UVB radiation was similar to that observed in cells lacking normal BRCA1 regulation [23]. This is
consistent with a publication demonstrating that oncogenic RAS and BRAF both cause misregulation of
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BRCA1 through a reduction in BRIP1 [12]. However, we were unable to demonstrate that this was due
to BRAF and instead conclude that the reduction in BRCA1 was a result of cells exiting the cell cycle
(Figure 8).
We have previously reported that expression of oncogenic BRAF attenuates the DNA damage induced
G2 checkpoint response [14]. Oncogenic BRAF induced phosphorylation of Chk1 at S280 (Figure 9).
This form of Chk1 has been reported to be altered in its function or regulation [27,29,30]. Finally, in
PMWK + TetON + V5-BRAF(V600E) cells, induction of oncogenic BRAF alone, exposure to UVB
alone or induction of oncogenic BRAF combined with exposure to UVB resulted in more chromosomal
aberrations than that observed in the RPMI8322 + TetON + V5-BRAF(V600E) cells. Both these lines
induced Chk1 pS280 equally suggesting that the potential altered regulation of Chk1 was not the entire
mechanism. Alterations in the SWI/SNF chromatin remodeling complex have been reported to sensitize
cells to UV radiation and attenuate the DNA damage G2 checkpoint response [34,40]. PMWK +
TetON + V5-BRAF(V600E) cells were found to not express BRG1. Unexpectedly RPMI8322 + TetON
+ V5-BRAF(V600E) cells were found to reduce the amount of BRG1 after induction of oncogenic
BRAF (Figure 10). Both cell lines exhibited reduced levels of BAF180 following V5-BRAF(V600E)
expression. This is the first report linking the MAP kinase pathway to the chromatin remodeling
pathway. Expression of oncogenic BRAF in cells results in elevated levels of Chk1pS280 and reduced
levels of BRG1 and BAF180 associated with attenuation of the G2 checkpoint response, clastogenesis,
and UVB sensitivity. While the cells used in this study were melanoma cells it is plausible that this
phenomenon will occur in melanocytes contained within nevi, since these melanocytes primarily contain
the oncogenic form of BRAF. Further studies will be required to establish the potential role of BRAF
induced clastogenesis and BRAF induced UVB sensitivity to the progression of melanoma from nevi.
However these data present an intriguing possibility for explaining the link between the risk associated
with increased nevi and the number of sunburns.
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